Program
Midazolam
Also written as “midazolam”, “USL261” and “SHP615”.
Its studies are mostly in Epilepsy · HIV Infections · Diabetes Mellitus, Type 2 · Neoplasms · Nervous System Diseases, led by 10 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 30 open or running | phase 1since Jul 1, 2008 | Jul 1, 2008 | none ahead |
| Merck | 30 open or running | phase 1since Jun 17, 2015 | Jun 17, 2015 | none ahead |
| Takeda | 30 open or running | phase 3since Nov 6, 2017 | Nov 6, 2017 | none ahead |
| Hamad Medical | 20 open or running | phase 4since Sep 4, 2016 | Sep 4, 2016 | none ahead |
| Johnson & Johnson | 20 open or running | phase 1since Oct 2, 2015 | Oct 2, 2015 | none ahead |
| Merck KGaA, Darmstadt, Germany | 10 open or running | phase 1since Aug 9, 2018 | Aug 9, 2018 | none ahead |
| Orion Corporation, Orion Pharma | 10 open or running | phase 3since May 31, 2007 | May 31, 2007 | none ahead |
| phathom-pharmaceuticals-inc | 10 open or running | phase 1since Sep 4, 2020 | Sep 4, 2020 | none ahead |
| rafa-laboratories | 10 open or running | phase 1since Dec 15, 2020 | Dec 15, 2020 | none ahead |
| the-emmes-company-llc | 10 open or running | phase 3since Apr 27, 2005 | Apr 27, 2005 | none ahead |
Also a collaborator on its studies: arvinas-estrogen-receptor-inc, National Resilience, takeda-development-center-americas-inc, pra-health-sciences, medpace-inc, premier-research-group-plc and cross-research-s-a.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Apr 27, 2005.
- Mar 10, 2009Phase 1 study in Healthy Male VolunteerAstraZeneca · NCT00859352 · 28 enrolled · Sweden
- Jun 17, 2015Merck's first study: phase 1 study in Skin Diseases, BacterialNew to MerckMerck · NCT02477514 · 18 enrolled
- Oct 2, 2015Johnson & Johnson's first study: phase 1 study in HealthyNew to Johnson & JohnsonJohnson & Johnson · NCT02568176 · 71 enrolled · Belgium
- Jun 2, 2016Phase 1 study in Healthy SubjectsJohnson & Johnson · NCT02791815 · 20 enrolled · France
- Sep 4, 2016Hamad Medical's first study: phase 4 study in SeizuresNew to Hamad MedicalHamad Medical · NCT02897856 · 150 enrolled · Qatar
- Oct 12, 2017Phase 1 study in Renal InsufficiencyMerck · NCT03311841 · 32 enrolled · United States
- Nov 6, 2017Takeda's first studies: 2 phase 3 studies in Nervous System DiseasesNew to TakedaTakeda · NCT03336645, NCT03336450
- Jan 29, 2018Phase 1 study in CarcinomaTakeda · NCT03420742 · 24 enrolled · France, Italy, Netherlands and more
- Aug 9, 2018Merck KGaA, Darmstadt, Germany's first study: phase 1 study in HealthyNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT03628339 · 12 enrolled · Germany
- Sep 4, 2020phathom-pharmaceuticals-inc's first study: phase 1 study in Healthy VolunteersNew to phathom-pharmaceuticals-incphathom-pharmaceuticals-inc · NCT04545944 · 20 enrolled · United States
- Sep 10, 2020Phase 3 study in Pain, ProceduralHamad Medical · NCT04571879 · 48 enrolled · Qatar
- Dec 15, 2020rafa-laboratories's first study: phase 1 study in Status EpilepticusNew to rafa-laboratoriesrafa-laboratories · NCT04679623 · 40 enrolled · United States
- Jul 1, 2021Phase 1 study in Solid TumourAstraZeneca · NCT04958226 · 21 enrolled · United States
- Aug 26, 2024Phase 1 study in Carcinoma, Non-Small-Cell LungMerck · NCT06575933 · 28 enrolled · United States
TargetBeta
“GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive allosteric modulator”ChEMBL 37, by rule
Other programs on the same 16 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ciprofolrule | Haisco Pharmaceutical Group | phase 4 | 36 |
| Alprazolamrule | Viatris | phase 4 | 35 |
| brexanolonerule | Supernus Pharmaceuticals | phase 4 | 14 |
| Diazepamrule | Acorda Therapeutics | phase 3 | 9 |
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06575933Carcinoma, Non-Small-Cell Lung · United States | 1 | Completed | Merck | Oct 28, 2024 | 28 |
| NCT04958226Solid Tumour · United States | 1 | Completed | AstraZeneca | Feb 6, 2023 | 21 |
| NCT04679623Status Epilepticus · United States | 1 | Completed | rafa-laboratories | Sep 17, 2021 | 40 |
| NCT04571879Pain, Procedural · Qatar | 3 | UNKNOWN | Hamad Medical | Dec 30, 2023 | 48 |
| NCT04545944Healthy Volunteers · United States | 1 | Completed | phathom-pharmaceuticals-inc | Nov 13, 2020 | 20 |
| NCT03628339Healthy · Germany | 1 | Completed | Merck KGaA, Darmstadt, Germany | Oct 25, 2018 | 12 |
| NCT03420742Carcinoma · France, Italy, Netherlands and more | 1 | Completed | Takeda | Mar 24, 2020 | 24 |
| NCT03336645Nervous System Diseases · Japan | 3 | Completed | Takeda | Aug 19, 2019 | 25 |
| NCT03336450Nervous System Diseases · Japan | 3 | Completed | Takeda | Oct 13, 2020 | 3 |
| NCT03311841Renal Insufficiency · United States | 1 | Completed | Merck | Aug 2, 2018 | 32 |
| NCT02897856Seizures · Qatar | 4 | Completed | Hamad Medical | Nov 2018 | 150 |
| NCT02791815Healthy Subjects · France | 1 | Completed | Johnson & Johnson | Sep 2016 | 20 |
| NCT02568176Healthy · Belgium | 1 | Completed | Johnson & Johnson | Feb 2016 | 71 |
| NCT02477514Skin Diseases, Bacterial | 1 | Completed | Merck | Aug 2015 | 18 |
| NCT00859352Healthy Male Volunteer · Sweden | 1 | Completed | AstraZeneca | 28 | |
| NCT00709553Healthy · Germany | 1 | Completed | AstraZeneca | Aug 2008 | 12 |
| NCT00481312Continuous Sedation in Initially Sedated Adults in ICU · Belgium, Estonia, Finland and more | 3 | Completed | Orion Corporation, Orion Pharma | Aug 2009 | 501 |
| NCT00109395Critical Illness · United States | 3 | Completed | the-emmes-company-llc | Sep 2007 | 179 |
How it is read
Names in the registry
- “Midazolam”, 63 entries
- “midazolam”, 13 entries
- “USL261”, 4 entries
- “SHP615”, 2 entries
- “Midazolam Solution”, 1 entry
Conditions, from the studies’ own filings
- Epilepsy, 4 studies
- HIV Infections, 2 studies
- Diabetes Mellitus, Type 2, 2 studies
- Neoplasms, 2 studies
- Nervous System Diseases, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.